• Explore /
  • Poster
  • / Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.

Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.

Abstract Video & Slides Poster

Authors

null

Matthew Raymond Smith

Massachusetts General Hospital Cancer Center, Boston, MA

Matthew Raymond Smith , Karim Fizazi , Teuvo L. J. Tammela , Felipe Melo Cruz , Luke T. Nordquist , Diana Sofia Aleman Polanco , Urban Emmenegger , Glauco Costa Silveira , Raoul S. Concepcion , Adriano Paula , Carlos Augusto de Mendonça Beato , Neil Fleshner , Martin Eduardo Richardet , Iris Kuss , Marie-Aude Le Berre , Gustavo Borghesi , Toni Sarapohja , Neal D. Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Localized Disease

Track

Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02200614

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 239)

DOI

10.1200/JCO.2021.39.6_suppl.239

Abstract #

239

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Alicia K. Morgans

Poster

2023 ASCO Genitourinary Cancers Symposium

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).

First Author: Daniel J. George

First Author: Karim Fizazi

First Author: Tomasz M. Beer